key: cord-0977334-1l6kg38l authors: Vedrines, Nicolas; Bouthors, Anne-Typhaine; Gayet, Stéphane; Lacout, Alexis title: Re -Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis date: 2020-10-28 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2020.10.018 sha: 7475a8f18c7635eb9da5ed3fdddb38ca2dd98c97 doc_id: 977334 cord_uid: 1l6kg38l nan To the Editor, We read with interest the paper of Fiolet et al [1] , which reviewed the effect of the hydroxychloroquine (HCQ) regimen alone or associated with azithromycin (AZI) on COVID19 mortality. For the effect of HCQ alone on mortality, we noted the following inaccuracies: 1. Fiolet et al. wrongly interpreted the relative risk (RR) in Geleris et al. [2] as that of mortality. The original work used the composite endpoint "intubation or death". Magagnoli et al. [3] . This RR was affected by length-biased sampling, suffered from a large amount of missing endpoints that was unbalanced across the groups (18% patients on HCQ, 12% patients on HCQ+AZI and 26% of controls were still hospitalized). Magagnoli et al. conducted a subanalysis to account for "the issue of length-biased sampling and differential rates of right-censored observations among the groups" and provide a better estimate of the RR. For the effect of HCQ+AZI on mortality, we noted: 3. Fiolet et al. mistakenly interpreted the RR in Rivera et al. [4] to be associated with HCQ+AZI regimen. The original work indicates this RR to be associated with "HCQ plus any other therapy", which was not limited to AZI since about 22% of these patients were not treated with AZI. In the light of these elements, we believe the authors should at minimum reconsider their conclusions. Hydroxychloroquine, azithromycine, COVID-19, coronavirus, meta-analysis The authors (NV, AT B, AL, SG) have nothing to disclose. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis Observational study of hydroxychloroquine in hospitalized patients with Covid-19 Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 Dexamethasone in hospitalized patients with Covid-19-preliminary report